TG Therapeutics, Inc.
TGTX
$48.74
$0.801.67%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 240.34M | 204.92M | 192.57M | 161.71M | 141.15M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 240.34M | 204.92M | 192.57M | 161.71M | 141.15M |
| Cost of Revenue | 41.19M | 33.51M | 38.14M | 28.09M | 18.94M |
| Gross Profit | 199.14M | 171.41M | 154.43M | 133.62M | 122.21M |
| SG&A Expenses | 82.13M | 88.22M | 62.75M | 63.37M | 55.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 218.66M | 170.12M | 142.08M | 132.34M | 106.31M |
| Operating Income | 21.67M | 34.80M | 50.49M | 29.37M | 34.84M |
| Income Before Tax | 10.23M | 20.36M | 45.09M | 25.91M | 30.92M |
| Income Tax Expenses | 2.45M | 586.00K | 22.06M | -364.99M | 2.73M |
| Earnings from Continuing Operations | 7.78M | 19.78M | 23.04M | 390.90M | 28.19M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.78M | 19.78M | 23.04M | 390.90M | 28.19M |
| EBIT | 21.67M | 34.80M | 50.49M | 29.37M | 34.84M |
| EBITDA | 21.73M | 34.83M | 50.52M | 29.38M | 34.86M |
| EPS Basic | 0.05 | 0.14 | 0.16 | 2.69 | 0.19 |
| Normalized Basic EPS | 0.05 | 0.13 | 0.20 | 0.11 | 0.13 |
| EPS Diluted | 0.05 | 0.12 | 0.14 | 2.43 | 0.17 |
| Normalized Diluted EPS | 0.04 | 0.12 | 0.18 | 0.10 | 0.12 |
| Average Basic Shares Outstanding | 141.77M | 144.44M | 142.96M | 145.42M | 146.74M |
| Average Diluted Shares Outstanding | 157.28M | 160.06M | 159.37M | 161.00M | 162.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |